Painreform Ltd (PRFX)

$1.02 +0.08 (8.51%)
Market Cap 1.93M
Revenue (ttm) 0.00
Net Income (ttm) -14.59M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 84,900
Avg Vol 352,880
Day's Range N/A - N/A
Shares Out 2.01M
Stochastic %K 81%
Beta 0.56
Analysts Strong Buy
Price Target $47.99

Company Profile

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and pain treatment of hernia repair operatio...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 972 3 7177050
Address:
65 Yigal Alon St., Tel Aviv, Israel
SPYmyQQQ
SPYmyQQQ Dec. 4 at 9:17 PM
🎯 Target Hit 🏁 📨 From Nov 19, 2025 💊 $PRFX 💵 Entry: $0.8800 ✅ Ext: $1.0342 💰 P/L: +17.52% 👉 FREE TRIAL! spymyqqq/join/
0 ¡ Reply
ShadowSnake
ShadowSnake Dec. 4 at 7:44 PM
$PRFX $2?
0 ¡ Reply
Tygalastkings187
Tygalastkings187 Dec. 4 at 7:32 PM
$PRFX buy now this things about to move
0 ¡ Reply
Tygalastkings187
Tygalastkings187 Dec. 4 at 7:27 PM
$PRFX back over $1!!! Next stop $2 then $3
0 ¡ Reply
ShadowSnake
ShadowSnake Dec. 4 at 6:38 PM
$PRFX
0 ¡ Reply
Tygalastkings187
Tygalastkings187 Dec. 4 at 6:12 PM
$PRFX on this news its slowly climbing!! Break the $1
0 ¡ Reply
Tygalastkings187
Tygalastkings187 Dec. 4 at 4:24 PM
$PRFX climbing slowly lets go back over $1
1 ¡ Reply
ShadowSnake
ShadowSnake Dec. 4 at 3:04 PM
$PRFX
1 ¡ Reply
Ashamo
Ashamo Dec. 3 at 3:12 AM
$PRFX let’s see if this runs PM!
0 ¡ Reply
Tygalastkings187
Tygalastkings187 Dec. 2 at 2:58 PM
$PRFX POSITIVE NEWS!!!!
0 ¡ Reply
Latest News on PRFX
PainReform Commences Development for OcuRing™-K Phase II Trial, LayerBio's Drop-Less Sustained-Release Ocular Therapy

Dec 2, 2025, 9:15 AM EST - 3 days ago

PainReform Commences Development for OcuRing™-K Phase II Trial, LayerBio's Drop-Less Sustained-Release Ocular Therapy

PainReform's DeepSolar Advances Development of its AI-Driven Automated Reporting Engine for Solar-Asset Analysis

Nov 12, 2025, 9:00 AM EST - 23 days ago

PainReform's DeepSolar Advances Development of its AI-Driven Automated Reporting Engine for Solar-Asset Analysis

PainReform's DeepSolar, Developing “DeepSolar Predict” within the NVIDIA Connect Program, Featured in The Market Link's “Watchlist Interview” and Announces Progress Toward Pilot Projects

Nov 5, 2025, 8:30 AM EST - 4 weeks ago

PainReform's DeepSolar, Developing “DeepSolar Predict” within the NVIDIA Connect Program, Featured in The Market Link's “Watchlist Interview” and Announces Progress Toward Pilot Projects

PainReform Provides Business Update for the Six Months Ended June 30, 2025

Oct 1, 2025, 9:27 AM EDT - 2 months ago

PainReform Provides Business Update for the Six Months Ended June 30, 2025

PainReform/DeepSolar Accepted into NVIDIA Connect Program

Aug 19, 2025, 8:30 AM EDT - 3 months ago

PainReform/DeepSolar Accepted into NVIDIA Connect Program

PainReform Ltd. Completes Strategic Investment in LayerBio to Enter $9B Global Cataract Surgery Market with Breakthrough Non-Opiate, Non-Steroidal Postoperative NSAID Drug Delivery System

Aug 13, 2025, 8:30 AM EDT - 4 months ago

PainReform Ltd. Completes Strategic Investment in LayerBio to Enter $9B Global Cataract Surgery Market with Breakthrough Non-Opiate, Non-Steroidal Postoperative NSAID Drug Delivery System

PainReform Ltd. enters into a Strategic Investment Agreement to Expand its Non-Opiate Pain Management Pipeline into Opthamology with LayerBio

Jul 10, 2025, 8:30 AM EDT - 5 months ago

PainReform Ltd. enters into a Strategic Investment Agreement to Expand its Non-Opiate Pain Management Pipeline into Opthamology with LayerBio

Blade Ranger: Consideration from PainReform Transaction Continues to Mature Following Growth in Software Sales

May 27, 2025, 12:12 PM EDT - 6 months ago

Blade Ranger: Consideration from PainReform Transaction Continues to Mature Following Growth in Software Sales

PainReform Launches Strategic AI Pilot with Econergy Using Its Proprietary DeepSolar™ Platform to Optimize One of Romania's Largest Solar Projects

May 7, 2025, 4:30 PM EDT - 7 months ago

PainReform Launches Strategic AI Pilot with Econergy Using Its Proprietary DeepSolar™ Platform to Optimize One of Romania's Largest Solar Projects

PainReform Expands into Home Energy Management Sector, Leveraging DeepSolar's AI-Driven Platform to Address the Growing Solar Optimization Market

Apr 10, 2025, 8:30 AM EDT - 8 months ago

PainReform Expands into Home Energy Management Sector, Leveraging DeepSolar's AI-Driven Platform to Address the Growing Solar Optimization Market

PainReform Provides Year-End Business Update

Apr 7, 2025, 5:00 PM EDT - 8 months ago

PainReform Provides Year-End Business Update

PainReform Completes Strategic Acquisition of DeepSolar, Unlocking New Growth Opportunities in AI-Driven Solar Analytics

Mar 5, 2025, 11:00 AM EST - 9 months ago

PainReform Completes Strategic Acquisition of DeepSolar, Unlocking New Growth Opportunities in AI-Driven Solar Analytics

PainReform Executes Definitive Agreement to Acquire DeepSolar, Marking a Unique Expansion Opportunity

Feb 18, 2025, 8:30 AM EST - 10 months ago

PainReform Executes Definitive Agreement to Acquire DeepSolar, Marking a Unique Expansion Opportunity

PainReform Provides Further Update on Phase 3 Clinical Trial of PRF-110

Dec 27, 2024, 8:30 AM EST - 1 year ago

PainReform Provides Further Update on Phase 3 Clinical Trial of PRF-110

PainReform Announces Initial Topline Data for PRF-110 Phase 3 Clinical Trial

Nov 20, 2024, 8:30 AM EST - 1 year ago

PainReform Announces Initial Topline Data for PRF-110 Phase 3 Clinical Trial

PainReform Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement

Nov 7, 2024, 5:00 PM EST - 1 year ago

PainReform Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement

PainReform Ltd. Confirms Sutures Compatibility in Human Clinical Trials for PRF-110

Sep 11, 2024, 8:30 AM EDT - 1 year ago

PainReform Ltd. Confirms Sutures Compatibility in Human Clinical Trials for PRF-110

PainReform Announces Exercise of Warrants for $1.58 Million Gross Proceeds

Sep 10, 2024, 9:46 AM EDT - 1 year ago

PainReform Announces Exercise of Warrants for $1.58 Million Gross Proceeds

PainReform Announces Positive Safety Profile for PRF-110 in Phase 3 Bunionectomy Study

Aug 20, 2024, 8:30 AM EDT - 1 year ago

PainReform Announces Positive Safety Profile for PRF-110 in Phase 3 Bunionectomy Study

PainReform Announces Favorable Safety Profile of PRF-110, Indicating Potential for Use in New Surgical Applications Requiring Higher Doses

Aug 7, 2024, 10:00 AM EDT - 1 year ago

PainReform Announces Favorable Safety Profile of PRF-110, Indicating Potential for Use in New Surgical Applications Requiring Higher Doses

PainReform's New Manufacturing Process Achieves Significant Benefits Including 18-Month Stability of PRF-110 at Room Temperature

Aug 1, 2024, 8:30 AM EDT - 1 year ago

PainReform's New Manufacturing Process Achieves Significant Benefits Including 18-Month Stability of PRF-110 at Room Temperature

PainReform Announces Receipt of Nasdaq Minimum Bid Price Notification

May 31, 2024, 4:15 PM EDT - 1 year ago

PainReform Announces Receipt of Nasdaq Minimum Bid Price Notification

PainReform Provides Business Update for the First Quarter of 2024

May 15, 2024, 4:05 PM EDT - 1 year ago

PainReform Provides Business Update for the First Quarter of 2024

PainReform CEO Ilan Hadar Discusses Latest Developments Related to PRF-110 and its Potential to Help Tackle the Opioid Epidemic on Proactiveinvestors.com

May 8, 2024, 8:30 AM EDT - 1 year ago

PainReform CEO Ilan Hadar Discusses Latest Developments Related to PRF-110 and its Potential to Help Tackle the Opioid Epidemic on Proactiveinvestors.com

PainReform Announces Closing of $4 Million Public Offering

Apr 18, 2024, 2:19 PM EDT - 1 year ago

PainReform Announces Closing of $4 Million Public Offering

PainReform's Non-Opiate Topical Treatment for Post-Surgical Pain Relief Outperforms Leading Competitor Under Various Testing Conditions

Apr 9, 2024, 9:00 AM EDT - 1 year ago

PainReform's Non-Opiate Topical Treatment for Post-Surgical Pain Relief Outperforms Leading Competitor Under Various Testing Conditions

PainReform Reaches 50% Enrollment in the Second Part of its Phase 3 Clinical Trial of PRF-110 in Bunionectomy

Apr 2, 2024, 8:30 AM EDT - 1 year ago

PainReform Reaches 50% Enrollment in the Second Part of its Phase 3 Clinical Trial of PRF-110 in Bunionectomy

PainReform to Present at the Microcap Conference in Atlantic City

Jan 22, 2024, 8:30 AM EST - 2 years ago

PainReform to Present at the Microcap Conference in Atlantic City

PainReform Reports Successful Head-to-Head Comparison of PRF-110 Versus Market Leading Post Surgical Analgesia for Extended Postoperative Pain Relief

Jan 3, 2024, 8:30 AM EST - 2 years ago

PainReform Reports Successful Head-to-Head Comparison of PRF-110 Versus Market Leading Post Surgical Analgesia for Extended Postoperative Pain Relief

PainReform Announces Exercise of Warrants for Approximately $1.3 Million in Gross Proceeds

Dec 26, 2023, 6:00 PM EST - 2 years ago

PainReform Announces Exercise of Warrants for Approximately $1.3 Million in Gross Proceeds

PainReform Provides Business Update for the Third Quarter of 2023

Nov 15, 2023, 4:05 PM EST - 2 years ago

PainReform Provides Business Update for the Third Quarter of 2023

PainReform Announces Plans to Commence Second Part of Phase 3 Clinical Trial to Evaluate PRF-110 in Patients Undergoing Bunionectomy Surgery Following Positive FDA Review of Drug Master File

Sep 11, 2023, 8:30 AM EDT - 2 years ago

PainReform Announces Plans to Commence Second Part of Phase 3 Clinical Trial to Evaluate PRF-110 in Patients Undergoing Bunionectomy Surgery Following Positive FDA Review of Drug Master File

PainReform Selected for Poster Presentation at the 13th Congress of the European Pain Federation in Budapest, Hungary

Sep 7, 2023, 10:00 AM EDT - 2 years ago

PainReform Selected for Poster Presentation at the 13th Congress of the European Pain Federation in Budapest, Hungary

PainReform to Participate in the H.C. Wainwright 25th Annual Global Investment Conference in New York City

Sep 5, 2023, 8:30 AM EDT - 2 years ago

PainReform to Participate in the H.C. Wainwright 25th Annual Global Investment Conference in New York City

PainReform Provides Business Update for the Second Quarter of 2023

Aug 10, 2023, 4:05 PM EDT - 2 years ago

PainReform Provides Business Update for the Second Quarter of 2023

PainReform Regains Compliance with Nasdaq Continued Listing Requirements

Jul 19, 2023, 9:00 AM EDT - 2 years ago

PainReform Regains Compliance with Nasdaq Continued Listing Requirements

PainReform Announces Pricing of $1.5 Million Concurrent Registered Direct Offering and Private Placement

Jul 14, 2023, 2:35 PM EDT - 2 years ago

PainReform Announces Pricing of $1.5 Million Concurrent Registered Direct Offering and Private Placement

PainReform Announces Pricing of $2.7 Million Concurrent Registered Direct Offering and Private Placement

Jul 12, 2023, 9:05 AM EDT - 2 years ago

PainReform Announces Pricing of $2.7 Million Concurrent Registered Direct Offering and Private Placement

PainReform to Present at the Maxim Group Virtual Healthcare Conference Hosted by M-Vest on June 21st

Jun 15, 2023, 8:30 AM EDT - 2 years ago

PainReform to Present at the Maxim Group Virtual Healthcare Conference Hosted by M-Vest on June 21st

PainReform Provides Regulatory Update on Second Part of its Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery

Jun 7, 2023, 4:30 PM EDT - 2 years ago

PainReform Provides Regulatory Update on Second Part of its Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery

PainReform Provides Business Update for the First Quarter of 2023

May 15, 2023, 4:45 PM EDT - 2 years ago

PainReform Provides Business Update for the First Quarter of 2023

PainReform Announces Positive Safety Data in First Part of Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery

May 1, 2023, 8:30 AM EDT - 2 years ago

PainReform Announces Positive Safety Data in First Part of Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery

PainReform Completes First Part of Phase 3 Clinical Trial in Patients Undergoing Bunionectomy Surgery

Mar 28, 2023, 9:10 AM EDT - 2 years ago

PainReform Completes First Part of Phase 3 Clinical Trial in Patients Undergoing Bunionectomy Surgery

PainReform Provides Year-End Business Update; Commences Phase 3 Clinical Trial of PRF-110 in Bunionectomy

Mar 16, 2023, 8:00 AM EDT - 2 years ago

PainReform Provides Year-End Business Update; Commences Phase 3 Clinical Trial of PRF-110 in Bunionectomy

PainReform Ltd. (NASDAQ: PRFX) Announces Receipt of Extension to Meet the Nasdaq's Minimum Bid Price Requirement

Feb 7, 2023, 4:05 PM EST - 3 years ago

PainReform Ltd. (NASDAQ: PRFX) Announces Receipt of Extension to Meet the Nasdaq's Minimum Bid Price Requirement

PainReform Provides Business Update for the Third Quarter of 2022

Nov 15, 2022, 8:30 AM EST - 3 years ago

PainReform Provides Business Update for the Third Quarter of 2022

PainReform to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Sep 1, 2022, 8:00 AM EDT - 3 years ago

PainReform to Present at the H.C. Wainwright 24th Annual Global Investment Conference

PainReform Provides Business Update for the Second Quarter of 2022

Aug 16, 2022, 8:05 AM EDT - 3 years ago

PainReform Provides Business Update for the Second Quarter of 2022

PainReform to Present at The Noble Capital Markets' Eighteenth Annual Investor Conference on April 20th

Apr 12, 2022, 9:00 AM EDT - 3 years ago

PainReform to Present at The Noble Capital Markets' Eighteenth Annual Investor Conference on April 20th

PainReform to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28th - 30th

Mar 21, 2022, 9:25 AM EDT - 4 years ago

PainReform to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28th - 30th

SPYmyQQQ
SPYmyQQQ Dec. 4 at 9:17 PM
🎯 Target Hit 🏁 📨 From Nov 19, 2025 💊 $PRFX 💵 Entry: $0.8800 ✅ Ext: $1.0342 💰 P/L: +17.52% 👉 FREE TRIAL! spymyqqq/join/
0 ¡ Reply
ShadowSnake
ShadowSnake Dec. 4 at 7:44 PM
$PRFX $2?
0 ¡ Reply
Tygalastkings187
Tygalastkings187 Dec. 4 at 7:32 PM
$PRFX buy now this things about to move
0 ¡ Reply
Tygalastkings187
Tygalastkings187 Dec. 4 at 7:27 PM
$PRFX back over $1!!! Next stop $2 then $3
0 ¡ Reply
ShadowSnake
ShadowSnake Dec. 4 at 6:38 PM
$PRFX
0 ¡ Reply
Tygalastkings187
Tygalastkings187 Dec. 4 at 6:12 PM
$PRFX on this news its slowly climbing!! Break the $1
0 ¡ Reply
Tygalastkings187
Tygalastkings187 Dec. 4 at 4:24 PM
$PRFX climbing slowly lets go back over $1
1 ¡ Reply
ShadowSnake
ShadowSnake Dec. 4 at 3:04 PM
$PRFX
1 ¡ Reply
Ashamo
Ashamo Dec. 3 at 3:12 AM
$PRFX let’s see if this runs PM!
0 ¡ Reply
Tygalastkings187
Tygalastkings187 Dec. 2 at 2:58 PM
$PRFX POSITIVE NEWS!!!!
0 ¡ Reply
ShadowSnake
ShadowSnake Dec. 2 at 2:36 PM
$PRFX great news yet no buyers 😡😡
1 ¡ Reply
MrTicker
MrTicker Dec. 2 at 2:20 PM
$PRFX BRIEF-Painreform Commences Development For Ocuring™-K Phase II Trial REUTERS 8:19 AM ET 12/2/2025 Dec 2 (Reuters) - PainReform Ltd(PRFX): * PAINREFORM COMMENCES DEVELOPMENT FOR OCURING™-K PHASE II TRIAL, LAYERBIO'S DROP-LESS SUSTAINED-RELEASE OCULAR THERAPY Source text: Further company coverage:
0 ¡ Reply
MrTicker
MrTicker Dec. 2 at 2:16 PM
$PRFX PainReform Commences Development for OcuRing™-K Phase II Trial, LayerBio’s Drop-Less Sustained-Release Ocular TherapyDevelopment plan positions OcuRing™-K for advancement in the fast-growing, multi-billion-dollar global cataract surgery market GLOBENEWSWIRE 8:15 AM ET 12/2/2025
0 ¡ Reply
Tygalastkings187
Tygalastkings187 Nov. 26 at 9:53 PM
$PRFX
0 ¡ Reply
max315
max315 Nov. 26 at 3:11 PM
$PRFX next
0 ¡ Reply
JohnTrack
JohnTrack Nov. 26 at 12:22 AM
$PRFX eyes on strength vs weakness...
0 ¡ Reply
JohnTrack
JohnTrack Nov. 25 at 10:10 PM
$PRFX Reverse split again, total garbage https://www.rapidticker.com/news/prfx-sec-filing-1f5b68
0 ¡ Reply
GreedyBastard4Ever
GreedyBastard4Ever Nov. 24 at 12:30 PM
$PRFX
1 ¡ Reply
max315
max315 Nov. 20 at 3:39 PM
$LFS watch $CDT $PRFX ticking up off of LFS (maybe) time for some overshorted micros to start popping. Love this time of year.
0 ¡ Reply
Tygalastkings187
Tygalastkings187 Nov. 20 at 12:56 PM
$PRFX
0 ¡ Reply
max315
max315 Nov. 19 at 9:25 PM
$CDT $BTC.X back over 90k following $NVDA earnings. Also $PRFX $CDT watching for tomorrow. Goodnight bears.
0 ¡ Reply
Tygalastkings187
Tygalastkings187 Nov. 19 at 8:37 PM
$PRFX 👀👀👀
0 ¡ Reply